MedTrace Logo

Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol

NCT01594619 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2014-10-15

No results posted yet for this study

Summary

Study in healthy volunteers to investigate the effects of Diltiazem on the Pharmacokinetics of naloxegol.

Conditions

  • Drug Induced Constipation

Interventions

DRUG

Naloxegol

Oral 25mg tablet

DRUG

Diltiazem XR

Oral 240mg tablet

Sponsors & Collaborators

Principal Investigators

  • Bo Fransson, MD · AstraZeneca, Sodertalje Sweden

  • Dave Matthews, MD · Quintiles, Inc Kansas Overland Park US

  • Mark Sostek, MD · AstraZeneca, Wilmington US

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01594619 on ClinicalTrials.gov